Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Business Wire

13 hours ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced 'bit by bio') Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt's capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026.
Aditxt is a social innovation platform that currently operates two programs focused on autoimmunity and early disease and cancer detection. The Company seeks to grow by A cquiring, B uilding, and C apitalizing high-growth ventures across health and biotechnology. The bitXbio Plan marks a deliberate move to broaden the company's capital accessibility and align its current market value with its commercialization roadmap — blending Bitcoin-backed reserve with capital access to support scale and liquidity.
'bitXbio™ is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline,' said Amro Albanna, Co-founder and CEO of Aditxt. 'As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds, and continue to utilize our equity line to support the commercialization of high-impact innovations. We believe that this approach positions us to unlock shareholder value as we strive to execute on planned monetization milestones, starting in 2026.'
Plan Highlights
Bitcoin-Backed Treasury Strategy
Aditxt plans to establish a Bitcoin reserve, subject to the availability of funds, to align its market value in support of its commercialization activities, and to unlock a new class of opportunities with digital asset economies.
Equity Line Facility
Aditxt intends to strategically deploy capital drawn on its existing equity line facility to meet its existing financial obligations and in support of its commercialization roadmap and upcoming monetization events. Aditxt has approximately $125 million in availability under its common stock purchase agreement with its equity line investor, of which it presently has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025.
Planned Capitalization Events in 2026
As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering.
The plan reflects Aditxt's broader vision to build a global, socially driven biotech platform, capable of commercializing and monetizing innovation through digital capitalization.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing," "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
For more information, please visit www.aditxt.com.
bitXbio™ is a trademark of Aditxt, Inc. All rights reserved.
Follow Aditxt on: